Safety and immunogenicity of a candidate parvovirus B19 vaccine
- 30 July 2011
- journal article
- research article
- Published by Elsevier
- Vol. 29 (43) , 7357-7363
- https://doi.org/10.1016/j.vaccine.2011.07.080
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- FluBlok, a recombinant hemagglutinin influenza vaccineInfluenza and Other Respiratory Viruses, 2008
- Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infectionEpidemiology and Infection, 2007
- Clinical aspects of parvovirus B19 infectionJournal of Internal Medicine, 2006
- Parvovirus B19 Infection Contributes to Severe Anemia in Young Children in Papua New GuineaThe Journal of Infectious Diseases, 2006
- Development of an improved method of detection of infectious parvovirus B19Journal of Clinical Virology, 2006
- Parvovirus B19New England Journal of Medicine, 2004
- Superior biologic activity of the recombinant bee venom allergen hyaluronidase expressed in baculovirus-infected insect cells as compared with Escherichia coli☆☆☆★★★Journal of Allergy and Clinical Immunology, 1998
- Type I skin reactivity to native and recombinant phospholipase A from honeybee venom is similarJournal of Allergy and Clinical Immunology, 1995
- Human parvovirus infection in homozygous sickle cell diseaseThe Lancet, 1993
- Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions.Proceedings of the National Academy of Sciences, 1991